These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 21387383)

  • 1. Antigen-specific adaptive immune responses in fingolimod-treated multiple sclerosis patients.
    Mehling M; Hilbert P; Fritz S; Durovic B; Eichin D; Gasser O; Kuhle J; Klimkait T; Lindberg RL; Kappos L; Hess C
    Ann Neurol; 2011 Feb; 69(2):408-13. PubMed ID: 21387383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis.
    Mehling M; Johnson TA; Antel J; Kappos L; Bar-Or A
    Neurology; 2011 Feb; 76(8 Suppl 3):S20-7. PubMed ID: 21339487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential effects of fingolimod (FTY720) on immune cells in the CSF and blood of patients with MS.
    Kowarik MC; Pellkofer HL; Cepok S; Korn T; Kümpfel T; Buck D; Hohlfeld R; Berthele A; Hemmer B
    Neurology; 2011 Apr; 76(14):1214-21. PubMed ID: 21464424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized trial of vaccination in fingolimod-treated patients with multiple sclerosis.
    Kappos L; Mehling M; Arroyo R; Izquierdo G; Selmaj K; Curovic-Perisic V; Keil A; Bijarnia M; Singh A; von Rosenstiel P
    Neurology; 2015 Mar; 84(9):872-9. PubMed ID: 25636714
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fingolimod: a novel immunosuppressant for multiple sclerosis.
    Brown BA; Kantesaria PP; McDevitt LM
    Ann Pharmacother; 2007 Oct; 41(10):1660-8. PubMed ID: 17785617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis.
    Mehling M; Lindberg R; Raulf F; Kuhle J; Hess C; Kappos L; Brinkmann V
    Neurology; 2010 Aug; 75(5):403-10. PubMed ID: 20592255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T-cell response against varicella-zoster virus in fingolimod-treated MS patients.
    Ricklin ME; Lorscheider J; Waschbisch A; Paroz C; Mehta SK; Pierson DL; Kuhle J; Fischer-Barnicol B; Sprenger T; Lindberg RL; Kappos L; Derfuss T
    Neurology; 2013 Jul; 81(2):174-81. PubMed ID: 23700335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of sphingosine 1-phosphate modulation on immune outcomes.
    Pinschewer DD; Brinkmann V; Merkler D
    Neurology; 2011 Feb; 76(8 Suppl 3):S15-9. PubMed ID: 21339486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distinct properties of circulating CD8+ T cells in FTY720-treated patients with multiple sclerosis.
    Johnson TA; Lapierre Y; Bar-Or A; Antel JP
    Arch Neurol; 2010 Dec; 67(12):1449-55. PubMed ID: 21149809
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis.
    Mehling M; Brinkmann V; Antel J; Bar-Or A; Goebels N; Vedrine C; Kristofic C; Kuhle J; Lindberg RL; Kappos L
    Neurology; 2008 Oct; 71(16):1261-7. PubMed ID: 18852441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Basic mechanisms of action of fingolimod in relation to multiple sclerosis].
    García-Merino JA; Sánchez AJ
    Rev Neurol; 2012 Jul; 55(1):31-7. PubMed ID: 22718407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Fingolimod - a new immunomodulator].
    Friedrich FW; Eschenhagen T
    Dtsch Med Wochenschr; 2009 Oct; 134(42):2127-31. PubMed ID: 19809964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suppressed pro-inflammatory properties of circulating B cells in patients with multiple sclerosis treated with fingolimod, based on altered proportions of B-cell subpopulations.
    Miyazaki Y; Niino M; Fukazawa T; Takahashi E; Nonaka T; Amino I; Tashiro J; Minami N; Fujiki N; Doi S; Kikuchi S
    Clin Immunol; 2014 Apr; 151(2):127-35. PubMed ID: 24607506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brain sphingosine-1-phosphate receptors: implication for FTY720 in the treatment of multiple sclerosis.
    Dev KK; Mullershausen F; Mattes H; Kuhn RR; Bilbe G; Hoyer D; Mir A
    Pharmacol Ther; 2008 Jan; 117(1):77-93. PubMed ID: 17961662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relapse of multiple sclerosis in a patient retaining CCR7-expressing T cells in CSF under fingolimod therapy.
    Yokoseki A; Saji E; Arakawa M; Hokari M; Ishiguro T; Yanagimura F; Ishihara T; Okamoto K; Nishizawa M; Kawachi I
    Mult Scler; 2013 Aug; 19(9):1230-3. PubMed ID: 23519973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fingolimod and sphingosine-1-phosphate--modifiers of lymphocyte migration.
    Massberg S; von Andrian UH
    N Engl J Med; 2006 Sep; 355(11):1088-91. PubMed ID: 16971715
    [No Abstract]   [Full Text] [Related]  

  • 17. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.
    Cohen JA; Barkhof F; Comi G; Hartung HP; Khatri BO; Montalban X; Pelletier J; Capra R; Gallo P; Izquierdo G; Tiel-Wilck K; de Vera A; Jin J; Stites T; Wu S; Aradhye S; Kappos L;
    N Engl J Med; 2010 Feb; 362(5):402-15. PubMed ID: 20089954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fingolimod for multiple sclerosis.
    Pelletier D; Hafler DA
    N Engl J Med; 2012 Jan; 366(4):339-47. PubMed ID: 22276823
    [No Abstract]   [Full Text] [Related]  

  • 19. Fingolimod for relapsing multiple sclerosis: an update.
    Horga A; Castilló J; Montalban X
    Expert Opin Pharmacother; 2010 May; 11(7):1183-96. PubMed ID: 20367536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Development of oral therapies for multiple sclerosis--fingolimod, cladribine and other drugs].
    Hecht B
    Med Monatsschr Pharm; 2010 Apr; 33(4):120-30; quiz 131-2. PubMed ID: 20429402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.